Emerging Alzheimer's disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions.

ABSTRACT: More than 55 million people suffer from dementia, with this number projected to double every 20 years. In the United States, 1 in 3 aged individuals dies from Alzheimer's disease (AD) or another type of dementia and AD kills more individuals than breast cancer and prostate cancer combined. AD is a complex and multifactorial disease involving amyloid plaque and neurofibrillary tangle formation, glial cell dysfunction, and lipid droplet accumulation (among other pathologies), ultimately leading to neurodegeneration and neuronal death. Unfortunately, the current FDA-approved therapeutics do not reverse nor halt AD. While recently approved amyloid-targeting antibodies can slow AD progression to improve outcomes for some patients, they are associated with adverse side effects, may have a narrow

SUBMITTER: Tobeh NS 

PROVIDER: S-EPMC10630922 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature